

ARTRYA

Coronary Heart Disease We See You


April 2025 Quarterly Call

1 May 2025



3Q FY2025 Quarterly Report

- Receives milestone Food and Drug Administration (FDA) 510(k) clearance for Salix® Coronary Anatomy for commercial sale in the US. Salix® Coronary Anatomy to be formally launched across hospital systems in the US
- Secures three-year commercial contracts with Sonic Healthcare Australia – Radiology and Lumus Imaging for the use of Salix® Coronary Anatomy platform
- Good progress made on clinical validation of Salix® Coronary Plaque (SCP) in preparation for FDA 510(k) submission. Ongoing development and calibration of Salix® Coronary Flow (SCF) product in preparation for FDA clinical study.
- Development of flagship study, SAPPHIRE to validate that Artrya's novel Plaque Dispersion Score (PDS) is a better risk predictor compared to current methods. Supports commercialisation in US
- Capital raise of \$15m was successfully completed post 31 March 2025 with cash balance totalling ~\$17m in early April 2025. Operational cash burn of \$4.60m for the quarter.



High Risk Plaque is difficult to see and rarely reported

Pathway to revenue

FDA Roadmap

1. Salix Coronary Anatomy (**FDA Cleared**)

Cleared on 28 March 2025

2. Salix Coronary Plaque (SCP)

Estimated clearance 3rd quarter CY25

3. Salix Coronary Flow (SCF)

Estimated clearance end of CY2025

Shortening the pathway to revenue

- First revenues from three US partners expected in CY25
- Scale the channel
 - Without need of large sales team
 - Existing KOL network
 - Accelerate SAPPHIRE Study
 - US centric Account Management, Integration, and Customer Support
- Existing customers in Australia

SAPPHIRE Study

Salix-based **A**nalysis of **P**laque to identify **P**atients at **H**igher **R**isk of **E**vents

SAPPHIRE aims to:

1. novel plaque dispersion score (PDS) better risk assessment compared to current methods
2. demonstrate that the PDS can be used to appropriately guide medical therapy
3. convert hospital systems participants to commercial agreements during study

Study Overview

- 3-phased study
 - 1) Feasibility
 - 2) Prognostic Value - Retrospective Arm
 - 3) RCT – Guiding Medical Therapy
- Multiple systems in US (6-8 systems identified)

Clinical Benefits

- Prognostic value (identifies patients at risk of future adverse events)
- Guides preventative/medical therapy
 - Initiation of medication
 - De-escalation/withdrawal of medical therapy

Salix[®] is built to target all pillars across the care continuum

Artrya's product pipeline goes further & moves us towards predicting the patient at risk.




Whole Heart Characterisation

Detailed Plaque and Dispersion

SCP
Salix[®] Coronary Plaque

Reimbursement – US\$950¹




Disease Severity

Non-invasive Blood Flow Assessment

SCF
Salix[®] Coronary Flow*

Reimbursement – US\$1,017¹



Structural Assessment

Structural & Aorta

SSA
Salix[®] Structural Assessment

Interventional Cardiologists



Optimised Procedure

Procedure & treatment

SPP
Salix[®] Procedure Planning

Interventional Cardiologists

Salix[®] Coronary Anatomy

Plaque Visualisation, Workflow Optimisation, Physician Productivity, CCTA reporting

SCA

Reimbursement – US\$357¹ per CCTA scan – FDA Cleared

¹ <https://cardiovascularbusiness.com/topics/cardiac-imaging/cms-increases-medicare-payments-cardiac-ct-ccta>

Thank You

